Reagent | sPLA2-IIA
Key benefits of the Randox sPLA2-IIA assay
Latex Enhanced Immunoturbidimetric method
Randox utilise the automated L.E.I method offering a more convenient and high performance method for sPLA2-IIA measurement compare to traditional ELISA testing.
Exceptional correlation with the standard method
A correlation coefficient of r=0.95 was displayed when the Randox methodology was compared against commercially available methods.
Liquid ready-to-use assay
The Randox sPLA2-IIA assay is available in a liquid ready-to-use format for convenience and ease-of-use.
Dedicated sPLA2-IIA controls and calibrator available
Randox offer dedicated sPLA2-IIA calibrator and controls, offering a complete testing package.
Applications are available
Applications are available detailing instrument-specific settings for the convenient use of the Randox sPLA2-IIA assay on a wide range of clinical chemistry analysers. Contact us to enquire about your specific analyser.
The secretory phospholipase A2 family comprises a large range of enzymes, their main function is to hydrolyse phospholipids from the cell membrane surface and lipoproteins. sPLA2-IIA is a prototypic member of the group II sPLA2 subfamily and has been shown to be induced by pro-inflammatory stimuli in a wide variety of cells and tissues. It has been found to be associated with a number of inflammatory diseases including, coronary artery disease, and atherosclerosis. These factors have contributed to its nickname, “inflammatory sPLA2” 1, 2.
Fig. 1 highlights the role of sPLA2-IIA in hydrolysing phospholipid from cell membrane surfaces, platelet-activating factor (PAF) and oxidativelymodified lipoproteins. Once hydrolysed, multiple bioactive lipids are produced including arachidonic acid which in turn is hydrolysed by cyclooxygenase to generate prostaglandins, lipoxygenase to produce lipoxines leukotriens and cytochromome P450 to generate epoxides fatty acid alcohols. In contrast, Lp-PLA2 requires oxidised phospholipids (ox-phosphatidyl-choline) as a substrate 3.
sPLA2-llA is already expressed in the normal arterial wall and its expression is readily up-regulated by inflammatory stimuli. Its role in producing fatty acids and biologically active phospholipids is linked to platelet, monocyte, and endothelial activation, processes known to be critical steps in atherogenesis 4. Research indicates that serum sPLA2-IIA levels are higher among CAD patients than normal subjects. The lipid mediators produced through sPLA2-IIA and their related lipids in the arterial wall can stimulate T cells and macrophages to synthesize and release the pro-atherogenic and pro-inflammatory cytokines, which in turn induce sPLA2-IIA production in the atherosclerotic walls 5.
1. European Heart Journal (2019): Group IIA secretory phospholipase A2, inflammation, and incident cardiovascular disease: An analysis from the JUPITER Trial 6
Objective: A study prospectively evaluated 17,802 patients enrolled in the JUPITER Trial to determine the association of sPLA2-IIA mass with incident CVD in a primary prevention population with chronic inflammation.
Conclusion: sPLA2-IIA plays an integral pro-inflammatory role in regulating vascular inflammation. The JUPITER trial found that elevated levels of sPLA2-IIA at baseline was significantly associated with a greater risk of incident CVD.
2. Journal of the American College of Cardiology (2013): Secretory phospholipase A2-IIA and cardiovascular disease: A Mendelian randomization study 7
Objective: A Mendelian randomisation meta-analysis prospectively examined 19 general population studies incorporating 8,021 incident, 7,513 prevalent major vascular events (MVE) in 74,684 patients and 10 acute coronary syndrome (ACS) cohorts incorporating 2,520 recurrent MVE in 18,355 patients to determine the role of sPLA2-IIA in cardiovascular disease (CVD).
Conclusion: sPLA2-IIA is thought to be the most highly expressed of the enzymes and observational studies have indicated that higher circulating sPLA2-IIA mass is associated with an increased risk of CVD and MVE.
 Role of secretory phospholipase A2 in women with metabolic syndrome. Pop, D, et al. 6, Cluj-Napoca : Indian Journal of Medical Research, 2013, Indian Journal of Medical Research, Vol. 138, pp. 866-872.
 Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention . Liu, PY, et al. 20, Tainan : European Heart Journal, 2003, Vol. 24.
 Group IIA Secretory Phospholipase A2, Vascular Inflammation, and Incident Cardiovascular Disease. Akinkuolie, AO, et al. 6, Boston : Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, Vol. 39.